Undiscounted | Discounted | |||||
---|---|---|---|---|---|---|
Palivizumab | No prophylaxis | Difference | Palivizumab | No prophylaxis | Difference | |
Life years | 66.51 | 66.34 | 0.17 | 27.15 | 27.08 | 0.07 |
Quality-adjusted life years by RSV history | 61.89 | 61.68 | 0.21 | 25.73 | 25.62 | 0.11 |
No RSV | 57.61 | 51.06 | 6.56 | 23.96 | 21.24 | 2.73 |
MA-RSV | 1.20 | 5.00 | −3.80 | 0.49 | 2.07 | −1.57 |
RSV-H | 3.08 | 5.63 | −2.55 | 1.27 | 2.31 | −1.05 |
Quality-adjusted life years by sequelae history | ||||||
No Sequelae | 61.28 | 60.25 | 1.03 | 25.25 | 24.51 | 0.74 |
Asthma | 0.16 | 0.34 | −0.18 | 0.13 | 0.27 | −0.14 |
Allergic sensitization | 0.33 | 0.84 | −0.51 | 0.26 | 0.66 | −0.40 |
Asthma and allergic sensitization | 0.12 | 0.24 | −0.12 | 0.09 | 0.19 | −0.10 |
Costs | € 4731 | € 3220 | € 1511 | € 4574 | € 2881 | € 1693 |
Prophylaxis costs | € 3100 | € 0 | € 3100 | € 3100 | € 0 | € 3100 |
MA-RSV: Medical care | € 2 | € 9 | -€ 7 | € 80 | € 334 | -€ 254 |
MA-RSV: Sequelae | € 100 | € 418 | -€ 318 | € 2 | € 9 | -€ 7 |
RSV-H: Medical care | € 1063 | € 1941 | -€ 879 | € 1042 | € 1904 | -€ 862 |
RSV-H: Sequelae | € 440 | € 803 | -€ 364 | € 326 | € 595 | -€ 269 |
RSV-H: Nosocomial | € 27 | € 49 | -€ 22 | € 27 | € 49 | -€ 22 |